Huons Co., Ltd. (243070.KQ)
KRW 24600.0
(-0.81%)
KRW 24600.0
(-0.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 50.47 Billion KRW | 124.88% |
| 2022 | 22.44 Billion KRW | -27.02% |
| 2021 | 30.75 Billion KRW | -44.67% |
| 2020 | 55.58 Billion KRW | 45.48% |
| 2019 | 38.2 Billion KRW | -15.53% |
| 2018 | 45.23 Billion KRW | 28.98% |
| 2017 | 35.06 Billion KRW | 128.71% |
| 2016 | 15.33 Billion KRW | 0.0% |
| 2014 | 20.93 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 9.88 Billion KRW | -1.35% |
| 2024 Q2 | 8.48 Billion KRW | -14.1% |
| 2023 Q2 | 14.77 Billion KRW | 6.18% |
| 2023 FY | 50.47 Billion KRW | 124.88% |
| 2023 Q4 | 10.01 Billion KRW | -14.87% |
| 2023 Q1 | 13.91 Billion KRW | 268.45% |
| 2023 Q3 | 11.76 Billion KRW | -20.37% |
| 2022 Q2 | 7.61 Billion KRW | -12.8% |
| 2022 Q4 | 3.77 Billion KRW | 62.3% |
| 2022 Q3 | 2.32 Billion KRW | -69.43% |
| 2022 Q1 | 8.72 Billion KRW | 951.33% |
| 2022 FY | 22.44 Billion KRW | -27.02% |
| 2021 Q2 | 8.59 Billion KRW | -3.53% |
| 2021 FY | 30.75 Billion KRW | -44.67% |
| 2021 Q1 | 8.9 Billion KRW | -60.71% |
| 2021 Q4 | -1.02 Billion KRW | -107.18% |
| 2021 Q3 | 14.28 Billion KRW | 66.24% |
| 2020 Q3 | 12.93 Billion KRW | 24.07% |
| 2020 Q1 | 9.55 Billion KRW | -4.56% |
| 2020 Q2 | 10.42 Billion KRW | 9.08% |
| 2020 FY | 55.58 Billion KRW | 45.48% |
| 2020 Q4 | 22.66 Billion KRW | 75.23% |
| 2019 Q2 | 7.95 Billion KRW | -16.22% |
| 2019 FY | 38.2 Billion KRW | -15.53% |
| 2019 Q4 | 10.01 Billion KRW | -6.83% |
| 2019 Q3 | 10.74 Billion KRW | 35.15% |
| 2019 Q1 | 9.49 Billion KRW | -22.65% |
| 2018 FY | 45.23 Billion KRW | 28.98% |
| 2018 Q2 | 10.49 Billion KRW | 18.88% |
| 2018 Q3 | 13.63 Billion KRW | 29.9% |
| 2018 Q1 | 8.82 Billion KRW | 2.87% |
| 2018 Q4 | 12.27 Billion KRW | -10.0% |
| 2017 Q1 | 9.8 Billion KRW | -12.3% |
| 2017 FY | 35.06 Billion KRW | 128.71% |
| 2017 Q4 | 8.58 Billion KRW | -11.04% |
| 2017 Q3 | 9.64 Billion KRW | 37.23% |
| 2017 Q2 | 7.03 Billion KRW | -28.3% |
| 2016 Q3 | 8.46 Billion KRW | 0.0% |
| 2016 FY | 15.33 Billion KRW | 0.0% |
| 2016 Q4 | 11.18 Billion KRW | 32.08% |
| 2014 FY | 20.93 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 359.802% |
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | -681.879% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | -137.353% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | -31.496% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | -6.991% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | 641.183% |
| Humedix Co., Ltd. | 24.82 Billion KRW | -103.35% |
| Boditech Med Inc. | 25.94 Billion KRW | -94.526% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 463.665% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | 852.324% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | -96.499% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | 518.459% |